Cardio-Oncology Education and Training: JACC Council Perspectives

Cardio-Oncology Education and Training: JACC Council Perspectives

The development of innovative cancer therapies has led to unprecedented improvement in survival outcomes and diverse treatment-related toxicities, including those with cardiovascular in nature. Aging population further increase the number of patients being treated for cancer, especially those with comorbidities. As existing and developing cardiovascular disease poses some the greatest risk of morbidity and mortality in patients with cancer.

Addressing the needs of complex cardiovascular patients has become increasingly important, which resulted in important for intersecting disciplines: cardio-oncology. Over the past decade, there has been a remarkable improvement of cardio-oncology clinics and service lines. This development, however, has occurred in a vacuum practice guidelines and training standards, although these are being actively pursued. In the document the board’s perspective, the authors describe the scope of practice in oncology and cardio-training requirements proposed, and the core competencies required. This document also serves as a road map to confirm cardio-oncology as a subspecialty of medicine.

The use of biomarkers to guide the selection of patients and therapies have gained a lot of attention to improving the scope and complexity of the selection of targeted therapy and immunotherapy. Clinical trials provide the basis for the discovery of biomarkers, which can then help in the development of new drugs. For that, a sample of cancer patients, including DNA, RNA, proteins, and metabolome isolated from cancerous tissue and blood or urine, is analyzed in a variety of ways to identify relevant biomarkers. In conjunction with the nucleotide-based, high-throughput, next-generation sequencing techniques, therapy-guided tests rely immunohistochemistry biomarker-based proteins play an important role in cancer treatment. In this review, we discuss the current knowledge of DNA and protein biomarkers for cancer immunotherapy.

both the primary and recurrence of cancer in patients after resection of colorectal cancer: An analysis of the integrated test with the Japan Clinical Oncology Group: JCOG1702A

Background: Improved early detection and treatment have resulted in an increase in the number of long-term victims of colorectal cancer (CRC). For the victims, a second primary cancers and recurrences are important issues; However, the evidence for the study of appropriate control strategies limited.This remnants aims to determine the frequency and timing of a second primary cancer in patients after surgery to explore the appropriate control strategies using an integrated analysis of three large-scale randomized controlled trials in Japan.

Methods: The eligibility criteria of the three trials included histologically confirmed CRC and receive operations. Time, location and frequency of second primary cancers and recurrences investigated. risk factors associated with a second primary cancer were also examined. standard incidence ratio (SIR) of a second primary cancer in comparison to the national database of the Cancer Registry of Japan is expected.
Results: A total of 2824 patients were included in this study. The cumulative incidence of second primary cancers increased from time to time. SIR of each second primary cancer was 1.07 (95% CI: 0.94 to 1.21). SIR for second primary cancers intestine was 1.09 (95% CI: 0.79 to 1.47). The cumulative incidence of recurrence nearly reached a plateau at 3 years.

Conclusions: A strategy for the general supervision of the general population can be applied even to patients curatively resected CRC, as a second primary cancer risk is nearly the same as the general population.

 Cardio-Oncology Education and Training: JACC Council Perspectives
Cardio-Oncology Education and Training: JACC Council Perspectives

Adherence to Oral Anticancer Therapeutics in Gynecologic Oncology Population

Introduction: To get a better understanding of gynecologic oncology patient compliance with oral anticancer agents through both cross-sectional survey of compliance and qualitative interviews with patients and physicians about their experiences with the drug.
Methods: Participants were eligible completing the survey for this cross-sectional study that included an assessment of compliance, distress, quality of life, and health literacy. Each woman takes oral anticancer agent for gynecological malignancies in a tertiary academic medical center for 30 days or more to qualify. semi-structured qualitative interviews (n = 14) was then performed to explore the experience with oral anticancer agent. We also perform qualitative group interviews with doctors and nurse practitioners.

Results: One hundred women taking oral anticancer agent listed. Fifty-four percent reported perfect adherence to their treatment, 21% reported a vague compliance (indicating at least one nonadherent behavior in the previous 7 days), and 25% reported non-compliance (indicating more than one behavior nonadherent within 7 days in advance). Qualitative analysis identified five main themes: the ease of use compared to traditional therapies; drugs self-administered mental burden; the perceived importance of the drug; management of side effects; and the desire for physician communication consistent. common misperception stated in an interview health care professionals including the high adherence to oral medication and a belief that the cost is the biggest barrier to compliance.

Human Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Hu-48Tests 48 Tests
EUR 331

Human Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Hu-96Tests 96 Tests
EUR 451

anti-PLGF

YF-PA13759 50 ug
EUR 363
Description: Mouse polyclonal to PLGF

anti-PLGF

YF-PA13760 100 ug
EUR 403
Description: Rabbit polyclonal to PLGF

Bovine Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-b-48T 48T
EUR 493
  • Should the Bovine Placenta Growth Factor (PLGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Bovine Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-b-96T 96T
EUR 641
  • Should the Bovine Placenta Growth Factor (PLGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Mouse Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Mu-48T 48T
EUR 317
  • Should the Mouse Placenta Growth Factor (PLGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Mouse Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Mu-96T 96T
EUR 398
  • Should the Mouse Placenta Growth Factor (PLGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Rat Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Ra-48T 48T
EUR 454
  • Should the Rat Placenta Growth Factor (PLGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Ra-96T 96T
EUR 587
  • Should the Rat Placenta Growth Factor (PLGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Bovine Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-b-48Tests 48 Tests
EUR 494

Bovine Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-b-96Tests 96 Tests
EUR 684

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Mu-48Tests 48 Tests
EUR 295

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Mu-96Tests 96 Tests
EUR 400

Rat Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Ra-48Tests 48 Tests
EUR 450

Rat Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Ra-96Tests 96 Tests
EUR 622

Bovine Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-b-48Tests 48 Tests
EUR 516

Bovine Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-b-96Tests 96 Tests
EUR 716

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Mu-48Tests 48 Tests
EUR 307

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Mu-96Tests 96 Tests
EUR 418

Rat Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Ra-48Tests 48 Tests
EUR 470

Rat Placenta Growth Factor (PLGF) ELISA Kit

RDR-PLGF-Ra-96Tests 96 Tests
EUR 651

Anti-PLGF antibody

STJ72011 100 µg
EUR 359

Rabbit Polyclonal antibody Anti-CRBN

Anti-CRBN 50 µg
EUR 349

Anti-PLGF-2 Antibody

A1303-100
EUR 338

Anti-PLGF-2 Antibody

A1303-30T
EUR 146

Anti-PLGF/PGF Antibody

PA1066 100ug/vial
EUR 294

Polyclonal Goat Anti-PLGF Antibody

AMM05090G 0.1 mg
EUR 484
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-PLGF . This antibody is tested and proven to work in the following applications:

PLGF Antibody

49602-100ul 100ul
EUR 333

PLGF Antibody

49602-50ul 50ul
EUR 239

PLGF protein

30R-2693 10 ug
EUR 325
Description: Purified recombinant Mouse PLGF protein

PlGF Antibody

5743-100
EUR 338

PlGF Antibody

5743-30T
EUR 146

PlGF antibody

70R-12427 100 ug
EUR 436
Description: Rabbit polyclonal PlGF antibody

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

Human PLGF ELISA Kit

EHP0025 96Tests
EUR 521

PLGF ELISA KIT|Human

EF000015 96 Tests
EUR 689

PLGF-1, human recombinant

4739-100
EUR 697

PLGF-1, human recombinant

4739-1000
EUR 3258

PLGF-1, human recombinant

4739-25
EUR 256

PLGF-2, human recombinant

4741-10
EUR 256

PLGF-2, human recombinant

4741-1000
EUR 3421

PLGF-2, human recombinant

4741-50
EUR 729

Human PLGF ELISA kit

LF-EK50333 1×96T
EUR 648

PLGF-3 Human Recombinant

P1563-10 10 µg
EUR 176

PLGF-3 Human Recombinant

P1563-50 50 µg
EUR 551

Human C-Peptide ELISA Kit

DLR-C-Peptide-Hu-48T 48T
EUR 398
  • Should the Human C-Peptide ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human C-Peptide ELISA Kit

DLR-C-Peptide-Hu-96T 96T
EUR 511
  • Should the Human C-Peptide ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human C-Peptide ELISA Kit

RD-C-Peptide-Hu-48Tests 48 Tests
EUR 387

Human C-Peptide ELISA Kit

RD-C-Peptide-Hu-96Tests 96 Tests
EUR 532

Human C-Peptide ELISA Kit

RDR-C-Peptide-Hu-48Tests 48 Tests
EUR 404

Human C-Peptide ELISA Kit

RDR-C-Peptide-Hu-96Tests 96 Tests
EUR 556

Polyclonal PlGF Antibody

AMR09382G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PlGF . This antibody is tested and proven to work in the following applications:

PLGF Conjugated Antibody

C49602 100ul
EUR 397

PLGF(PLGF93) Antibody

BNC610093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC680093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC680093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC680094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC680094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC040093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC040093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC040094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC040094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC400093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC400093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC400094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC400094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC470093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC470093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC470094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC470094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNUM0093-50 50uL
EUR 395
Description: Primary antibody against PLGF(PLGF93), 1mg/mL

PLGF(PLGF94) Antibody

BNUM0094-50 50uL
EUR 395
Description: Primary antibody against PLGF(PLGF94), 1mg/mL

PLGF(PLGF93) Antibody

BNC700093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC940093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC940093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC940094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC940094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCA0093-250 250uL
EUR 383
Description: Primary antibody against PLGF(PLGF93), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCA0094-250 250uL
EUR 383
Description: Primary antibody against PLGF(PLGF94), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCP0093-250 250uL
EUR 383
Description: Primary antibody against PLGF(PLGF93), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCP0094-250 250uL
EUR 383
Description: Primary antibody against PLGF(PLGF94), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCR0093-250 250uL
EUR 383
Description: Primary antibody against PLGF(PLGF93), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCR0094-250 250uL
EUR 383
Description: Primary antibody against PLGF(PLGF94), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCB0093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCB0093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCB0094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCB0094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC880093-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF93), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC880093-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF93), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC880094-100 100uL
EUR 199
Description: Primary antibody against PLGF(PLGF94), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC880094-500 500uL
EUR 544
Description: Primary antibody against PLGF(PLGF94), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNUB0093-100 100uL
EUR 209
Description: Primary antibody against PLGF(PLGF93), Concentration: 0.2mg/mL

PLGF(PLGF93) Antibody

BNUB0093-500 500uL
EUR 458
Description: Primary antibody against PLGF(PLGF93), Concentration: 0.2mg/mL

PLGF(PLGF94) Antibody

BNUB0094-100 100uL
EUR 209
Description: Primary antibody against PLGF(PLGF94), Concentration: 0.2mg/mL

PLGF(PLGF94) Antibody

BNUB0094-500 500uL
EUR 458
Description: Primary antibody against PLGF(PLGF94), Concentration: 0.2mg/mL

PLGF Rabbit pAb

A1727-100ul 100 ul
EUR 308

PLGF Rabbit pAb

A1727-200ul 200 ul
EUR 459

PLGF Rabbit pAb

A1727-20ul 20 ul
EUR 183

PLGF Rabbit pAb

A1727-50ul 50 ul
EUR 223

PLGF Rabbit pAb

A16257-100ul 100 ul
EUR 308

PLGF Rabbit pAb

A16257-200ul 200 ul
EUR 459

PLGF Rabbit pAb

A16257-20ul 20 ul
EUR 183

PLGF Rabbit pAb

A16257-50ul 50 ul
EUR 223

PLGF, murine recombinant

4743-10
EUR 245

PLGF, murine recombinant

4743-1000
EUR 5433

PLGF, murine recombinant

4743-50
EUR 756

PlGF-1 Antibody

5739-100
EUR 338

PlGF-1 Antibody

5739-30T
EUR 146

ELISA kit for Human PLGF

EK5213 96 tests
EUR 553
Description: Enzyme-linked immunosorbent assay kit for quantification of Human PLGF in samples from serum, plasma, tissue homogenates and other biological fluids.

Human PLGF PicoKine ELISA Kit

EK0490 96 wells
EUR 436
Description: For quantitative detection of human PLGF in cell culture supernates, serum, plasma(heparin, EDTA, citrate) and urine.

PLGF-2, human recombinant protein

P1056-.01 10 µg
EUR 300
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.

PLGF-2, human recombinant protein

P1056-.05 50 µg
EUR 877
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.

PLGF-2, human recombinant protein

P1056-1 1 mg
EUR 4156
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.

Human PLGF ELISA kit (4X96T)

LF-EK50334 4×96T
EUR 2201

Recombinant Human PlGF-3 Protein

PROTP49763-6 25ug
EUR 317
Description: PlGF-3 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-3 is expressed exclusively in the placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-3 lacks heparin binding affinity. Recombinant human PlGF-3 is a 45.7 kDa disulfide-linked homodimeric protein of two 203 amino acid polypeptide chains.

Recombinant Human PlGF-1 Protein

PROTP49763-7 25ug
EUR 317
Description: PlGF-1 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-1 is expressed in placental tissues, colon and mammary carcinomas. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. Recombinant human PlGF-1 is a 29.7 kDa disulfide-linked homodimeric protein of two 132 amino acid polypeptide chains.

Recombinant Human PlGF-2 Protein

PROTP49763-8 25ug
EUR 317
Description: PLGF-2 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PLGF-2 is expressed in umbilical vein endothelial cells and placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-2 also signals through Neuropilin (NP-1) and can bind with high affinity to heparin. Recombinant human PLGF-2 is a 34.0 kDa disulfide-linked homodimeric protein of two 150 amino acid polypeptide chains.

PLGF ELISA Kit (Human) (OKBB00242)

OKBB00242 96 Tests
EUR 518
Description: Description of target: The protein, also called PGF, is 149 amino acids long and shares 53% identity with the platelet-derived growth factor-like region of human VPF. And the N-glycosylated PLGF protein is secreted into the medium and that it functions as a dimer1. The PLGF gene is mapped to 14q24-q31. There are 3 isoforms of PGF, designated PGF1, PGF2, and PGF3. Only PGF2 is able to bind heparin. Additionally, PGF regulates inter- and intramolecular cross-talk between the VEGF receptor tyrosine kinases FLT1 and FLK12. It also can stimulate angiogenesis and collateral growth in ischemic heart and limb with at least a comparable efficiency to VEGF3.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 1 pg/mL

Polyclonal PlGF-1 Antibody

AMR09383G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PlGF-1 . This antibody is tested and proven to work in the following applications:

Goat PLGF ELISA Kit

EGTP0025 96Tests
EUR 521

Bovine PLGF ELISA Kit

EBP0025 96Tests
EUR 521

Chicken PLGF ELISA Kit

ECKP0025 96Tests
EUR 521

Canine PLGF ELISA Kit

ECP0025 96Tests
EUR 521

Anserini PLGF ELISA Kit

EAP0025 96Tests
EUR 521

Porcine PLGF ELISA Kit

EPP0025 96Tests
EUR 521

Rat PLGF ELISA Kit

ERP0025 96Tests
EUR 521

Rabbit PLGF ELISA Kit

ERTP0025 96Tests
EUR 521

Sheep PLGF ELISA Kit

ESP0025 96Tests
EUR 521

Monkey PLGF ELISA Kit

EMKP0025 96Tests
EUR 521

Conclusion: Nearly half of the patients surveyed reported vague or non-compliance with their oral anticancer agent. Qualitative interviews identified several important themes, many of which are not recognized by physicians and nurse practitioners. These findings highlight the need for the patient and health care professional interventions to improve patient adherence.